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Surgical Resection for Patients With Mucinous
Bronchioloalveolar Carcinoma
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Kenji Ono, Tomoko So, Mitsuhiro Takenoyama and Kosei Yasumoto, Second Department of Surgery, 
School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
BACKGROUND: The clinical features of mucinous bronchioloalveolar carcinoma (BAC) have remained
unclear due to the low incidence of this disease. This study investigated the clinicopathological features
and the surgical outcome in patients with mucinous BAC.
METHODS: We clinicopathologically evaluated 782 patients who underwent resection for nonsmall cell
carcinoma between 1999 and 2008, of whom, 13 (1.6%) demonstrated to have mucinous BAC.
RESULTS: The patients with mucinous BAC included six men and seven women. The mean age was 69.1
years (range: 55–78 years). Eight patients (61.5%) had a smoking habit. No patients had any subjective
symptoms. The tumour diameter ranged from 1.2 cm to 10 cm. The surgical procedures included 11
lobectomies, and two partial resections of affected lobes. The pathological stage was IA in eight patients,
IB in two, IIA in two, and IIIA in one. None of the patients had lymph node metastases or lymphovascular
invasion. The overall postoperative 5-year survival rate was 52.5%. The 5-year survival rate according to
tumour diameter was 100% in patients with tumours ≤ 3 cm, and 25.1% in patients with tumours > 3 cm.
Two patients died due to pulmonary metastases, and one died from carcinomatous pleuritis and 
pulmonary metastases.
CONCLUSION: Patients with small mucinous BAC (≤ 3 cm) in diameter showed excellent prognosis
after surgical resection. However, mucinous BAC > 3 cm in diameter tended to recur with pulmonary
metastasis. [Asian J Surg 2010;33(2):89–93]
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Introduction
The incidence of lung cancer is still increasing, and it is
the leading cause of cancer-related mortality in many
industrialized countries.1,2 Despite years of multidiscipli-
nary management and research, the prognosis of patients
with lung cancer remains dismal, and the 5-year survival
rate is reported to be 10–15% throughout the world.3,4 It
is usually diagnosed at a regionally advanced or incurable
metastatic stage. Early detection of lung cancer and cura-
tive surgical resection are considered to be the most
important countermeasures to reduce mortality. However,
recent advances in imaging diagnostic technology have
enabled the detection of early-stage lung cancer.5 The
widespread use of computed tomography (CT) for screen-
ing of lung cancer or evaluation of other chest diseases
can be associated with detection of small peripheral carci-
noma, such as bronchioloalveolar carcinoma (BAC).6
BAC has historically been recognised as a subtype of
pulmonary adenocarcinoma in which tumour cells spread
out along the alveolar septa (lepidic growth pattern).7
BAC was more precisely defined in the 1999 World Health
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Organization classification as an adenocarcinoma that
shows growth of neoplastic cells along pre-existing alveo-
lar structures, without evidence of stromal, vascular or
pleural invasion.8 BAC is divided into mucinous, nonmu-
cinous, and mixed subtypes. Mucinous BAC is composed
of neoplastic tall columnar cells with apical cytoplasmic
mucin and basally oriented nuclei. This distinction is
based upon histological criteria; mucinous and nonmuci-
nous BAC have different characteristics in therapeutic
and prognostic implications.9 This study retrospectively
investigated the clinicopathological features of patients
with mucinous BAC who underwent surgery.
Patients and methods
Patients
The hospital records of 782 consecutive patients who un-
derwent resection of nonsmall cell lung cancer (NSCLC)
between 1999 and 2008 were reviewed. The preoperative
assessments included chest roentgenography, and CT of
the chest, upper abdomen and brain. The clinical N2 sta-
tus was defined by the presence of a lymph node with 
a short diameter of > 1 cm. Bone scintigraphy was per-
formed to detect any bone metastasis. Magnetic reso-
nance imaging of the brain was routinely employed after
2001. Bronchoscopy was routinely performed to obtain a
pathological diagnosis by transbronchial lung biopsy, and
to evaluate endobronchial staging. The patients’ records,
including clinical data, preoperative examination results,
details of any surgical operations, histopathological find-
ings, and the TNM stages were also reviewed. The pul-
monary function was evaluated using spirometry and
arterial blood gas analysis. A ventilation–perfusion scan
was routinely performed to predict postoperative lung
function. The predictive postoperative lung function was
considered to be sufficient if the forced vital capacity and
forced expiratory volume in 1 second as a percentage of
forced vital capacity was > 900 mL/m2 and > 600 mL/m2,
respectively.10 All resected specimens, including the pri-
mary tumour and resected hilar and mediastinal lymph
nodes, were examined to determine both the tumour 
histology and extent of lymph node metastases. The
histopathological findings were classified according 
to the World Health Organization criteria, and the Inter-
national Union Against Cancer TNM staging system 
(7th edition) was employed.8,11 Mucinous BAC was defined
as an adenocarcinoma with a pure lepidic growth pattern,
in which alveolar walls were lined by a cellular prolifera-
tion of columnar cancer cells with abundant apical mucin
and small basally oriented nuclei. The diagnosis was per-
formed by haematoxylin and eosin staining.
Follow-up information was obtained from all patients
through office visits or telephone interviews either with
the patient, a relative, or their primary physician. The pa-
tients were evaluated every 3 months by chest roentgenog-
raphy, and chest CT and bone scintigraphy examinations
performed every 6 months for the first 2 years after surgery,
and annually thereafter. The mean observation time was
3.3 years.
Epidermal growth factor receptor gene (EGFR) 
mutation analysis
Genomic DNA was extracted and purified from either
fresh frozen tumours or tumours embedded in paraffin
blocks. DNA isolation was performed as previously de-
scribed.12 The screening method for detection of in-frame
deletion in exon 19 and the L858R point mutation in
exon 21 has also been described previously.13
Detection of K-ras mutation using polymerase chain 
reaction-based restriction fragment length polymorphism
The designed restriction fragment length polymorphism
method for the detection of K-ras codon 12 mutations
has been described previously.14 Wild-type alleles were
digested and they yielded a smaller product (77 bp) 
than mutant forms (97 bp), which were resistant to diges-
tion. The sense-primer sequence was 5-AAACTTGTG-
GTAGTTGGACCT-3, and the antisense primer was
5-CTATTGTTGGATCATATTCG-3.
Statistical analyses
The survival curve was calculated by the Kaplan–Meier
method and compared using the Log-rank test for uni-
variate analysis. Categorical variables were compared by
Fisher’s exact test. The differences were considered to be
significant if p was < 0.05. The Statview 5.0 software
(Abacus Concepts, Berkeley, CA, USA) was used for all 
statistical analyses.
Results
Seven hundred and eighty-two patients underwent resec-
tion for NSCLC between 1999 and 2008. Among them,
163 patients (20.8%) were diagnosed with BAC (including
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nonmucinous and mucinous BAC). There were 13 (1.6%)
patients with mucinous BAC. They included six men and
seven women (Table 1). The median age of the patients
was 72 years (range: 55–78 years). Eight patients (61.5%)
had a smoking habit. Three patients were detected by
annual medical check-up, and eight were diagnosed dur-
ing evaluation for other diseases. Two patients had subjec-
tive symptoms (cough and pneumothorax, respectively).
Tumour diameters ranged from 1.2 cm to 10 cm. Tumour
diameters in six patients were diagnosed as T1a (≤ 2 cm).
Seven out of the 13 patients showed a cavitary lesion in
the tumour on CT. Three patients were diagnosed by trans-
bronchial lung biopsy before surgery, and 10 patients
were diagnosed by intraoperative frozen section.
Lobectomy was performed in 11 patients, and partial
resection of the affected lobe in two. The pathological
stage was IA in eight patients, IB in two, IIA in two, and IIIA
in one. The patients in stage IIIA had pulmonary metastasis
in the ipsilateral different lobe of the primary tumour,
which was resected with the primary tumour. Complete
resection was performed in all 13 patients, and the surgi-
cal margin of each patient was cancer-free pathologically.
None of the patients had lymph node metastases, and no
lymphovascular invasion surrounding the tumours was
identified pathologically. The overall postoperative 5-year
survival rate was 52.5% (Figure 1). The 5-year survival rate
according to tumour diameter was 100% in patients with
tumours ≤ 3 cm, and 25.1% in patients with tumours > 3 cm
(Figure 2). Two patients died due to pulmonary metas-
tases, and one died from carcinomatous pleuritis and pul-
monary metastases. One patient was alive with pulmonary
metastases 2 years after surgical resection, and nine were
alive and well without any recurrence.
The EGFR and K-ras mutation status of mucinous
BAC was also examined. No patients among the 10 from
whom surgical specimens were available for DNA extrac-
tion revealed any mutations in EGFR (in-frame deletion
in exon 19 and the L858R point mutation in exon 21). 
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Table 1. Characteristics of patients with mucinous bronchi-
oloalveolar carcinoma who underwent a surgical resection
Average of age (range) 69.1 (55–78)
Gender (M/F) 6/7
Smoker/nonsmoker 8/5
Cause of initial detection
Evaluation for other diseases 8
Medical checkup 3
Subjects symptoms 2
Operative procedure
Lobectomy 11
Partial resection 2
Pathological stage
T1aN0M0 stage IA 6
T1bN0M0 stage IA 2
T2aN0M0 stage IB 2
T2bN0M0 stage IIA 2
T4N0M0 stage IIIA 1
Recurrence sites
Pulmonary metastases + carcinomatous 1
pleuritis
Pulmonary metastases 3
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Figure 1. Overall survival curves of the patients with mucinous
bronchioloalveolar carcinoma. The postoperative 5-year survival
rate was 52.5%.
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Figure 2. Survival curves of the patients with mucinous bron-
chioloalveolar carcinoma according to tumour size. The post-
operative 5-year survival rate was 100% in patients with tumours
≤ 3 cm, and 25.1% in patients with tumours > 3 cm.
In contrast, a K-ras mutation was detected in three (33%)
of nine specimens available for DNA mutation analysis.
Discussion
BAC represents less than 4% of all NSCLC, although the
incidence of BAC has recently increased due to advances in
imaging diagnostic technology over the past two decades.15
BACs are classified into mucinous and nonmucinous 
subtypes. Mucinous BAC is a relatively rare subtype of
lung cancer. Mucinous BAC is composed of goblet or
mucin-producing cells, whereas nonmucinous BAC shows
predominantly Clara cell or type II pneumocyte differen-
tiation.16,17 Mucins are a family of high-molecular-weight,
heavily glycosylated proteins, and are the main compo-
nents of mucus. Microscopically, they consist of neoplastic
elements that float in large mucin pools and focally line
the alveolar spaces. The aberrant expression of MUC3
(membrane-bound mucin) and MUC6 (secreted mucin)
has been reported to serve as a diagnostic marker of muci-
nous BAC.18
Mucinous BAC is more likely to develop diffuse disease
with parenchymal opacification based on CT findings,
whereas nonmucinous BAC presents as ground-glass
opacity nodules.19 Lee et al20 have reported that CT atten-
uation values are significantly higher for mucinous BAC
than for non-mucinous BAC. However, both subtypes of
BAC are difficult to distinguish by positron emission to-
mography because of scant fluorodeoxyglucose uptake.20,21
Seven out of the 13 patients in the current series revealed
a cavitary lesion in the tumour. Cavity formation is not
common in nonmucinous BAC.22 However, mucinous
BAC produces copious mucus, which floods the alveoli
within the tumour-cell nests and causes bronchorrhoea
and cavity formation.23 Therefore, a cavitary lesion with
ground-glass opacity is one of the clinical characteristics
of mucinous BAC. Although bronchorrhoea is a late man-
ifestation, mucinous BAC has been suggested to be the
most prone to develop an aerogenous spread as intrapul-
monary metastasis, in comparison with nonmucinous
BAC, which leads to an unfavourable prognosis.24–26 One
of the current patients had pulmonary metastasis in the
ipsilateral different lobe of the primary tumour at the
time of diagnosis, and three patients died from pul-
monary metastases.
Nonmucinous BAC is reported to be less dependent
on tobacco exposure, and disproportionately affects women
and persons of East Asia origin.9,27,28 However, 61.5% of
our patients had a smoking habit and almost half of them
were male. Sartori et al29 have reported that an active
smoking habit is significantly associated with mucinous
BAC, in contrast to the nonmucinous type. Furthermore,
several investigators have reported different characteris-
tics in molecular biology between the two subtypes: non-
mucinous BAC seems driven more by the EGFR pathway,
whereas mucinous BAC is driven by mutations of K-ras, a
potent oncogene.30,31 Therefore, mucinous BAC appears
to be resistant to EGFR tyrosine kinase inhibitors.31 It is
important to distinguish mucinous from nonmucinous
subtypes of BAC because of the therapeutic and prognostic
implications. None of the patients in the present series had
any somatic mutations in the EGFR gene, whereas K-ras
mutation was detected in 33.3% of patients. Mutations of
EGFR and K-ras have been detected in 35% and 9% of lung
adenocarcinoma, respectively.13 These findings suggest a
distinct mechanism in the development of mucinous
BAC and other types of lung adenocarcinoma.
This study retrospectively investigated the clinico-
pathological features of patients with mucinous BAC. No
patients had subjective symptoms and 61% were diagnosed
at IA stage. Pathological examination revealed neither
mediastinal lymph node metastasis nor lymphovascular
invasion surrounding the tumours in any of the patients.
The patients with smaller mucinous BAC (≤ 3 cm in diam-
eter) showed excellent prognosis after surgical resection;
however, the tumours > 3 cm in diameter tended to recur
with pulmonary metastasis. Early diagnosis with com-
plete surgical resection is therefore important for the
patients with mucinous BAC.
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